All Blogs

Aug 16, 2019

The recent acquisition of Relief Therapeutics by Sonnet BioTherapeutics will surely fuel the growth of Chemotherapy-Induced Peripheral Neuropathy (CIPN) therapy market. Sonnet plans to commence the development of its promising candidate SON-080 for CIPN treatment. Peripheral Neuropathy is a set of complications cau...

Aug 15, 2019

EU recommends the use of Imbruvica for two new indications The Janssen Pharmaceutical has received the approval for its drug Imbruvica (ibrutinib) from the European Commission (EC). Ibrutinib is a first-in-class targeted therapy, which inhibits the function of Bruton's tyrosine kinase (BTK). Jointly developed an...

Aug 14, 2019

Psoriasis is a debilitating inflammation of skin affecting approximately 7.4 million adults in the United States. Recent researches demonstrating a surge in the Psoriasis prevalence indicating moderate-to-severe psoriasis, absence of safe, effective and easy to administer therapies has clearly resulted in several m...

Aug 13, 2019

GNA Biosolutions nets USD 13.5 Million in a Series C Funding GNA Biosolutions has secured USD 13.5 Million completing its all the rounds of financing. GNA Biosolutions GmbH, a Germany-based molecular diagnostics company has been able to successfully secure IVD-CE marking of its first point-of-care (POC) molecul...

Aug 12, 2019

Psoriasis is a skin inflammation which is a papulosquamous disease with variable morphology, distribution, severity, course, and duration.According to the WHO report 2016, studies on Psoriasis epidemiology have demonstrated varying prevalence rates across the globe (0.09–11.4%), with an apparent upward trend in sev...

Aug 09, 2019

Niemann–Pick disease type C (NPC) is a rare genetic disorder which progress and worsens with time. Affecting males and females, DelveInsight estimated the total Niemann–Pick disease type C prevalent population in the 7MM around 2116 in 2017, and the total diagnosed NPC prevalent population was observed to be 1,058....

Aug 08, 2019

Vesselon Acquires FDA-Approved lipid microsphere drug Imagent Vesselon, an oncology therapeutics company, today acquired an FDA-approved drug Imagent for diagnostic purposes as a contrast agent for diagnostic ultrasound. Vesselon’s Vascular Encapsulation Sonication Targeting (VESTTM) system incorporates three FD...

Aug 07, 2019

The Human immunodeficiency virus (HIV) cases have grown to pandemic extents since the first case of acquired immunodeficiency syndrome (AIDS) was reported in 1981. CDC estimates that approximately 1.1 million people in the U.S. are living with HIV today. About 15 per cent of them (1 in 7) are unaware of their infec...

Aug 06, 2019

FDA approves first Tenosynovial giant cell tumour treatment Turalio (Pexidartinib) The US FDA has given its approval to Turalio (pexidartinib) capsules for the treatment of symptomatic tenosynovial giant cell tumour (TGCT) associated with severe morbidity or functional limitations that surgery has failed to impr...

Aug 05, 2019

Failure in suppressing epilepsy; steps away from seizure-freedom Epilepsy, a central nervous system disorder that hinders the normal functioning of the brain, and leads to abnormality and loss of awareness. It affects over 70 million people worldwide, wherein nearly a quarter of patients with seizures have drug-...